[4-Aminoquinoline-sensitivity of Plasmodium falciparum in Madagascar. II. Study in two regions of the east coast].
In Manakara and Foulpointe (East Coast of Madagascar) 184 malarial patients were selected among 742 patients attending dispensaries. The 7 days in vivo tests was performed in 144 patients. 13/36 failure to alternative (10 mg/kg) and 1/61 failure to standard (25 mg/kg) chloroquine WHO tests were observed. 10 mg/kg oral amodiaquine failed within 7 days in 5/47 patients. The in vitro semi-microtest was performed with 27 isolates. 2/24 Plasmodium falciparum isolates were chloroquino-resistant (IC50 = 270 and 280 nM/1), 27/27 were sensitive to low doses of amodiaquine (max IC50 = 76 nM/1), 25/25 were very sensitive to dichlorquinazine (max IC50 = 83 nM/1) and with pipéraquine 22/24 were very sensitive (IC50 less than 75 nM/1) and 2 less sensitive (IC50 = 240 and greater than 140 nM/1).
D000634:Aminoquinolines / Q000627:therapeutic use*; D000655:Amodiaquine / Q000627:therapeutic use; D000962:Antimalarials; D002648:Child; D002738:Chloroquine / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D008270:Madagascar; D008288:Malaria / Q000188:drug therapy* / Q000453:epidemiology; D010879:Piperazines / Q000627:therapeutic use; D010963:Plasmodium falciparum / Q000187:drug effects*; D011804:Quinolines / Q000627:therapeutic use
D000634:Aminoquinolines; D000962:Antimalarials; D010879:Piperazines; D011804:Quinolines; C043112:dichlorquinazine; D000655:Amodiaquine; D002738:Chloroquine; C034759:piperaquine
Sensibilité aux amino-4-quinoleines de Plasmodium falciparum a Madagascar: II. Etude en deux regions de la cote est.